Ultibro Breezhaler

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
01-09-2021
Karakteristik produk Karakteristik produk (SPC)
01-09-2021

Bahan aktif:

indacaterol, Glycopyrronium bromide

Tersedia dari:

Novartis Europharm Limited

Kode ATC:

R03AL04

INN (Nama Internasional):

indacaterol, glycopyrronium bromide

Kelompok Terapi:

Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids, Drugs for obstructive airway diseases,

Area terapi:

Pulmonary Disease, Chronic Obstructive

Indikasi Terapi:

Ultibro Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Ringkasan produk:

Revision: 13

Status otorisasi:

Authorised

Tanggal Otorisasi:

2013-09-19

Selebaran informasi

                                39
B. PACKAGE LEAFLET
40
PACKAGE LEAFLET: INFORMATION FOR THE USER
ULTIBRO BREEZHALER 85 MICROGRAMS/43 MICROGRAMS INHALATION POWDER, HARD
CAPSULES
indacaterol/glycopyrronium
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ultibro Breezhaler is and what it is used for
2.
What you need to know before you use Ultibro Breezhaler
3.
How to use Ultibro Breezhaler
4.
Possible side effects
5.
How to store Ultibro Breezhaler
6.
Contents of the pack and other information
Instructions for use of Ultibro Breezhaler inhaler
1.
WHAT ULTIBRO BREEZHALER IS AND WHAT IT IS USED FOR
WHAT ULTIBRO BREEZHALER IS
This medicine contains two active substances called indacaterol and
glycopyrronium. These belong to
a group of medicines called bronchodilators.
WHAT ULTIBRO BREEZHALER IS USED FOR
This medicine is used to make breathing easier for adult patients who
have breathing difficulties due to
a lung disease called chronic obstructive pulmonary disease (COPD). In
COPD the muscles around the
airways tighten. This makes breathing difficult. This medicine blocks
the tightening of these muscles
in the lungs, making it easier for air to get in and out of the lungs.
If you use this medicine once a day, it will help to reduce the
effects of COPD on your everyday life.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE ULTIBRO BREEZHALER
DO NOT USE ULTIBRO BREEZHALER
-
if you are allergic to indacaterol or glycopyrronium or any of the
other ingredients of this
medicine (listed in section 6).
41
WARNINGS AND PRECAUTIONS
Talk
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Ultibro Breezhaler 85 micrograms/43 micrograms inhalation powder hard
capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 143 micrograms of indacaterol maleate equivalent
to 110 micrograms of
indacaterol and 63 micrograms of glycopyrronium bromide equivalent to
50 micrograms of
glycopyrronium.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 110 micrograms of
indacaterol maleate equivalent to 85 micrograms of indacaterol and 54
micrograms of glycopyrronium
bromide equivalent to 43 micrograms of glycopyrronium.
Excipient(s) with known effect
Each capsule contains 23.5 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Capsules with transparent yellow cap and natural transparent body
containing a white to almost white
powder, with the product code “IGP110.50” printed in blue under
two blue bars on the body and the
company logo (
) printed in black on the cap.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ultibro Breezhaler is indicated as a maintenance bronchodilator
treatment to relieve symptoms in adult
patients with chronic obstructive pulmonary disease (COPD).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is the inhalation of the content of one capsule
once daily using the Ultibro
Breezhaler inhaler.
Ultibro Breezhaler is recommended to be administered at the same time
of the day each day. If a dose
is missed, it should be taken as soon as possible on the same day.
Patients should be instructed not to
take more than one dose in a day.
Special populations
_Elderly population _
Ultibro Breezhaler can be used at the recommended dose in elderly
patients (75 years of age and
older).
3
_Renal impairment _
Ultibro Breezhaler can be used at the recommended dose in patients
with mild to moderate renal
impairment. In patients with severe renal impair
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 01-09-2021
Karakteristik produk Karakteristik produk Bulgar 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Bulgar 03-10-2013
Selebaran informasi Selebaran informasi Spanyol 01-09-2021
Karakteristik produk Karakteristik produk Spanyol 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Spanyol 03-10-2013
Selebaran informasi Selebaran informasi Cheska 01-09-2021
Karakteristik produk Karakteristik produk Cheska 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Cheska 03-10-2013
Selebaran informasi Selebaran informasi Dansk 01-09-2021
Karakteristik produk Karakteristik produk Dansk 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Dansk 03-10-2013
Selebaran informasi Selebaran informasi Jerman 01-09-2021
Karakteristik produk Karakteristik produk Jerman 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Jerman 03-10-2013
Selebaran informasi Selebaran informasi Esti 01-09-2021
Karakteristik produk Karakteristik produk Esti 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Esti 03-10-2013
Selebaran informasi Selebaran informasi Yunani 01-09-2021
Karakteristik produk Karakteristik produk Yunani 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Yunani 03-10-2013
Selebaran informasi Selebaran informasi Prancis 01-09-2021
Karakteristik produk Karakteristik produk Prancis 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Prancis 03-10-2013
Selebaran informasi Selebaran informasi Italia 01-09-2021
Karakteristik produk Karakteristik produk Italia 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Italia 03-10-2013
Selebaran informasi Selebaran informasi Latvi 01-09-2021
Karakteristik produk Karakteristik produk Latvi 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Latvi 03-10-2013
Selebaran informasi Selebaran informasi Lituavi 01-09-2021
Karakteristik produk Karakteristik produk Lituavi 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Lituavi 03-10-2013
Selebaran informasi Selebaran informasi Hungaria 01-09-2021
Karakteristik produk Karakteristik produk Hungaria 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Hungaria 03-10-2013
Selebaran informasi Selebaran informasi Malta 01-09-2021
Karakteristik produk Karakteristik produk Malta 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Malta 03-10-2013
Selebaran informasi Selebaran informasi Belanda 01-09-2021
Karakteristik produk Karakteristik produk Belanda 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Belanda 03-10-2013
Selebaran informasi Selebaran informasi Polski 01-09-2021
Karakteristik produk Karakteristik produk Polski 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Polski 03-10-2013
Selebaran informasi Selebaran informasi Portugis 01-09-2021
Karakteristik produk Karakteristik produk Portugis 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Portugis 03-10-2013
Selebaran informasi Selebaran informasi Rumania 01-09-2021
Karakteristik produk Karakteristik produk Rumania 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Rumania 03-10-2013
Selebaran informasi Selebaran informasi Slovak 01-09-2021
Karakteristik produk Karakteristik produk Slovak 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Slovak 03-10-2013
Selebaran informasi Selebaran informasi Sloven 01-09-2021
Karakteristik produk Karakteristik produk Sloven 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Sloven 03-10-2013
Selebaran informasi Selebaran informasi Suomi 01-09-2021
Karakteristik produk Karakteristik produk Suomi 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Suomi 03-10-2013
Selebaran informasi Selebaran informasi Swedia 01-09-2021
Karakteristik produk Karakteristik produk Swedia 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Swedia 03-10-2013
Selebaran informasi Selebaran informasi Norwegia 01-09-2021
Karakteristik produk Karakteristik produk Norwegia 01-09-2021
Selebaran informasi Selebaran informasi Islandia 01-09-2021
Karakteristik produk Karakteristik produk Islandia 01-09-2021
Selebaran informasi Selebaran informasi Kroasia 01-09-2021
Karakteristik produk Karakteristik produk Kroasia 01-09-2021
Laporan Penilaian publik Laporan Penilaian publik Kroasia 03-10-2013

Peringatan pencarian terkait dengan produk ini